Scarica l'app Stockscreener
49.30
2.90%
1.56
Dopo l'orario di chiusura:
49.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$47.74
Aprire:
$49.23
Volume 24 ore:
21.38M
Relative Volume:
1.06
Capitalizzazione di mercato:
$73.28B
Reddito:
$20.62B
Utile/perdita netta:
$3.56B
Rapporto P/E:
20.67
EPS:
2.3847
Flusso di cassa netto:
$3.48B
1 W Prestazione:
+6.79%
1M Prestazione:
+10.15%
6M Prestazione:
-35.59%
1 anno Prestazione:
-52.28%
Intervallo 1D:
$48.88
$50.16
Intervallo di 1 settimana:
$44.43
$50.16
Portata 52W:
$42.20
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
49.30 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
107.96 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
337.43 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.92 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
EW
Edwards Lifesciences Corp
|
89.33 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-30 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Downgrade | Erste Group | Buy → Hold |
| 2025-09-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
Boston Scientific earnings on deck as WATCHMAN slowdown looms By Investing.com - Investing.com Canada
UBS lowers Boston Scientific stock price target on valuation reset By Investing.com - Investing.com Canada
Boston Scientific Restructures Operations, Plans Workforce Cuts - Medical Product Outsourcing
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
Canaccord reiterates Boston Scientific stock rating after restructuring - Investing.com
Boston Scientific Corp (BSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fears for Irish jobs as Boston Scientific plans global restructuring - Business Post
What To Expect From Boston Scientific’s (BSX) Q2 Earnings - Barchart.com
Boston Scientific Announces 2026 Global Restructuring Plan to Drive Cost Efficiencies and Growth - Minichart
Boston Scientific to restructure, cut costs by $500M annually - NBC Boston
Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case - Law360
Boston Scientific unveils new restructuring plan, expects job cuts - Reuters
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific (NYSE: BSX) sets $700–$800 million restructuring with $500 million savings - Stock Titan
Boston Scientific Overturns $42M Patent Verdict - Intellectia AI
Boston Scientific Gets $42 Million Stent Patent Verdict Reversed - Bloomberg Law News
Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today - Benzinga
Boston Scientific Corp (BSX) Cash Flow - TradingKey
Boston Scientific Corporation (BSX) Options Chain - Yahoo! Finance Canada
Boston Scientific Corp (BSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Boston Scientific Corp (BSX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Boston Scientific (BSX) Faces FDA Advisory Over Transcarotid Sys - GuruFocus
Boston Scientific (BSX) Faces Potential Device Risk Notification - GuruFocus
Boston Scientific Corp (BSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Boston Scientific Corp (BSX) Institutional Confidence - TradingKey
Boston Scientific Corp (BSX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - GlobeNewswire Inc.
BSX|Boston Scientific Corp|Price:45.500|Chg%:+1.250 - TradingKey
BSX|Boston Scientific Corp|Price:44.265|Chg%:+0.685 - TradingKey
Boston Scientific stock trades firm as cardiovascular revenue grows and TAVR momentum supports earni - AD HOC NEWS
Daily Brief Health Care: Boston Scientific, Mitesco Inc, Samsung Biologics and more - Smartkarma
Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial - Yahoo! Finance Canada
AAFMAA Wealth Management & Trust LLC's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific stock trades steady as recent earnings and cardiovascular portfolio shape investor - AD HOC NEWS
Boston Scientific Settles With Stryker In Spine Device IP Fight - Law360
Goldman Sachs Launches $510 Million Autocallable Notes Linked to Boston Scientific Stock Performance - Kalkine Media
Boston Scientific Corporation (BSX) Stock forecasts - Yahoo Finance UK
Boston Scientific, Stryker Settle Surgical Device Patent Dispute - Bloomberg Law News
Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump - Yahoo Finance
Boston Scientific stock trades steadily as device maker grows revenue and prepares for next earnings - Ad-hoc-news.de
Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued - Yahoo Finance
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors despite losses on the day - MarketWatch
Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock? - Yahoo Finance
Boston Scientific stock advances on strong sales and margin gains - Ad-hoc-news.de
Boston Scientific to Combine Light Manufacturing, Global Distribution in Indiana Expansion - Assembly Magazine
Boston Scientific stock holds gains as cardiovascular revenue grows and new devices support long ter - Ad-hoc-news.de
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
Boston Scientific stock trades steady as latest earnings highlight growth and margin focus - ad-hoc-news.de
The Bull Case For Boston Scientific (BSX) Could Change Following Global Recall Of CRE Endoscopy Devices - simplywall.st
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Boston Scientific Corp Azioni (BSX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Monson Jonathan | EVP and CFO |
Jul 01 '26 |
Option Exercise |
0.00 |
2,087 |
0 |
40,073 |
| Pegus Cheryl | Director |
May 20 '26 |
Buy |
56.49 |
1,770 |
99,987 |
1,770 |
| LUDWIG EDWARD J | Director |
May 20 '26 |
Buy |
56.68 |
3,580 |
202,914 |
25,359 |
| Habiger David C | Director |
May 20 '26 |
Buy |
55.92 |
2,250 |
125,819 |
13,878 |
| Habiger David C | Director |
May 19 '26 |
Buy |
56.95 |
2,200 |
125,279 |
11,628 |
| O'Connor Padraig Andrew | EVP, Global Operations |
May 02 '26 |
Option Exercise |
0.00 |
1,802 |
0 |
7,896 |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC |
May 02 '26 |
Option Exercise |
0.00 |
2,102 |
0 |
57,894 |
| Woodworth Emily | SVP, Global Controller and CAO |
Mar 01 '26 |
Option Exercise |
0.00 |
838 |
0 |
3,231 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 16 '26 |
Option Exercise |
0.00 |
905 |
0 |
6,433 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 14 '26 |
Option Exercise |
0.00 |
1,190 |
0 |
5,977 |
0.40%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):